The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of pazopanib (PAZ) in combination with PCI-24781 (PCI) in patients (pts) with metastatic solid tumors with new tumor proliferation imaging correlates in renal cell carcinoma (RCC) and sarcoma.
Thach-Giao Truong
No relevant relationships to disclose
Jennifer A. Grabowsky
No relevant relationships to disclose
Stephanie Chen
No relevant relationships to disclose
Roth Ea
No relevant relationships to disclose
Andrew H. Ko
No relevant relationships to disclose
Terence W. Friedlander
No relevant relationships to disclose
Emily K. Bergsland
No relevant relationships to disclose
Andrea Lynne Harzstark
No relevant relationships to disclose
Anne Reinert
No relevant relationships to disclose
Gordon Fung
No relevant relationships to disclose
Adil Daud
Research Funding - GlaxoSmithKline (I); Pharmacyclics (I)
Pamela N. Munster
Research Funding - GlaxoSmithKline; Pharmacyclics